-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17

Benzinga·07/10/2026 12:28:48
Listen to the news
Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $17.